113 related articles for article (PubMed ID: 37303939)
1. PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis.
Wang H; Zhou Y; Zhang S; Qi YA; Wang M
Oncol Res; 2021; 29(4):275-289. PubMed ID: 37303939
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
3. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.
Wang J; Ye C; Liu J; Hu Y
Biochem Biophys Res Commun; 2018 Jul; 501(4):1034-1040. PubMed ID: 29777711
[TBL] [Abstract][Full Text] [Related]
4. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract][Full Text] [Related]
5. CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR-506-3p/NFIB axis.
Ying H; Zhao R; Yu Q; Zhang K; Deng Q
Drug Dev Res; 2022 Apr; 83(2):512-524. PubMed ID: 34541682
[TBL] [Abstract][Full Text] [Related]
6. Circ_0025033 deficiency suppresses paclitaxel resistance and malignant development of paclitaxel-resistant ovarian cancer cells by modulating the miR-532-3p/FOXM1 network.
Huang H; Yan L; Zhong J; Hong L; Zhang N; Luo X
Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):275-286. PubMed ID: 35196944
[TBL] [Abstract][Full Text] [Related]
7. Overexpressed COL5A1 is correlated with tumor progression, paclitaxel resistance, and tumor-infiltrating immune cells in ovarian cancer.
Zhang J; Zhang J; Wang F; Xu X; Li X; Guan W; Men T; Xu G
J Cell Physiol; 2021 Oct; 236(10):6907-6919. PubMed ID: 33655494
[TBL] [Abstract][Full Text] [Related]
8. GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24/Siglec-10 Axis.
Chen C; Zhang L; Ruan Z
Mol Pharm; 2023 Feb; 20(2):971-986. PubMed ID: 36547230
[TBL] [Abstract][Full Text] [Related]
9. LncRNA SNHG16 promotes proliferation and migration in laryngeal squamous cell carcinoma via the miR-140-5p/NFAT5/Wnt/β-catenin pathway axis.
Wan L; Gu D; Li P
Pathol Res Pract; 2022 Jan; 229():153727. PubMed ID: 34911016
[TBL] [Abstract][Full Text] [Related]
10. Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Guo Z; Zhang J; Fan L; Liu J; Yu H; Li X; Sun G
Med Sci Monit; 2019 Mar; 25():2079-2086. PubMed ID: 30893293
[TBL] [Abstract][Full Text] [Related]
11. Long non-‑coding RNA SNHG16 functions as a tumor activator by sponging miR‑373‑3p to regulate the TGF‑β‑R2/SMAD pathway in prostate cancer.
Weng W; Liu C; Li G; Ruan Q; Li H; Lin N; Chen G
Mol Med Rep; 2021 Dec; 24(6):. PubMed ID: 34643247
[TBL] [Abstract][Full Text] [Related]
12. LncRNA SNHG16 promotes epithelial- mesenchymal transition via down-regulation of DKK3 in gastric cancer.
Zhou C; Zhao J; Liu J; Wei S; Xia Y; Xia W; Bi Y; Yan Z; Huang H
Cancer Biomark; 2019; 26(4):393-401. PubMed ID: 31561329
[TBL] [Abstract][Full Text] [Related]
13. NCK1-AS1 promotes NCK1 expression to facilitate tumorigenesis and chemo-resistance in ovarian cancer.
Chang H; Li B; Zhang X; Meng X
Biochem Biophys Res Commun; 2020 Feb; 522(2):292-299. PubMed ID: 31761329
[TBL] [Abstract][Full Text] [Related]
14. Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis.
Li B; Jin X; Meng H; Hu B; Zhang T; Yu J; Chen S; Guo X; Wang W; Jiang W; Wang J
Oncotarget; 2017 Jul; 8(29):47849-47860. PubMed ID: 28599307
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA SNHG16 promotes cell growth and metastasis in ovarian cancer.
Yang XS; Wang GX; Luo L
Eur Rev Med Pharmacol Sci; 2018 Feb; 22(3):616-622. PubMed ID: 29461589
[TBL] [Abstract][Full Text] [Related]
16. HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
Jiang J; Wang S; Wang Z; Cai J; Han L; Xie L; Han Q; Wang W; Zhang Y; He X; Yang C
Cancer Chemother Pharmacol; 2020 Aug; 86(2):295-305. PubMed ID: 32743678
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
[TBL] [Abstract][Full Text] [Related]
18. A transcription factor that promotes proliferation, migration, invasion, and epithelial-mesenchymal transition of ovarian cancer cells and its possible mechanisms.
Qi Y; Mo K; Zhang T
Biomed Eng Online; 2021 Aug; 20(1):83. PubMed ID: 34399777
[TBL] [Abstract][Full Text] [Related]
19. SNHG5 enhances Paclitaxel sensitivity of ovarian cancer cells through sponging miR-23a.
Lin H; Shen L; Lin Q; Dong C; Maswela B; Illahi GS; Wu X
Biomed Pharmacother; 2020 Mar; 123():109711. PubMed ID: 31884343
[TBL] [Abstract][Full Text] [Related]
20. CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro.
Zhu Z; Mu Y; Qi C; Wang J; Xi G; Guo J; Mi R; Zhao F
Int J Mol Med; 2015 Feb; 35(2):340-8. PubMed ID: 25516145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
